☆ 4.1 Review

Role of Atogepant in the Treatment of Episodic Migraines: Clinical Perspectives and Considerations

THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2022)

Related references

Note: Only part of the references are listed.

Article Pharmacology & Pharmacy

Atogepant: First Approval

Emma D. Deeks

Summary: Atogepant is an orally administered CGRP receptor antagonist developed by AbbVie for the prophylaxis of migraine. It has been approved in the USA for preventive treatment of episodic migraine in adults, with ongoing phase 3 clinical development in other countries. This article summarizes the milestones in atogepant's development leading to its first approval for preventive treatment of episodic migraine in adults.

DRUGS (2022)

Add to Collection

Article Multidisciplinary Sciences

Prevalence and impact of visual aura in migraine and probable migraine: a population study

Kyung Min Kim et al.

Summary: The prevalence of visual aura is similar in patients with migraine and probable migraine, but in the presence of visual aura, patients experience higher headache frequency, more severe cutaneous allodynia, and greater disability.

SCIENTIFIC REPORTS (2022)

Add to Collection

Review Pharmacology & Pharmacy

CGRP receptor antagonists for migraine. Are they also AMY1 receptor antagonists?

Michael L. Garelja et al.

Summary: The development of drugs targeting the CGRP system has been a major breakthrough in migraine management. These drugs can be classified into antibodies and receptor antagonists, with receptor antagonists further divided into small molecule antagonists and antibody antagonists. While antagonists are most potent at the CGRP receptor, they may also show antagonism at the AMY(1) receptor, indicating the need for further research.

BRITISH JOURNAL OF PHARMACOLOGY (2022)

Add to Collection

Article Clinical Neurology

Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial

Todd J. Schwedt et al.

Summary: Atogepant showed treatment benefits as early as the first full day after initiation, and maintained efficacy throughout each 4-week interval during the 12-week treatment period.

CEPHALALGIA (2022)

Add to Collection

Article Clinical Neurology

Combined onabotulinumtoxinA/atogepant treatment blocks activation/sensitization of high-threshold and wide-dynamic range neurons

Agustin Melo-Carrillo et al.

Summary: The study showed that combined treatment with OnabotulinumtoxinA and atogepant prevented activation and sensitization of trigeminovascular neurons induced by cortical spreading depression, potentially offering more effective relief for chronic migraine patients compared to monotherapy.

CEPHALALGIA (2021)

Add to Collection

Article Medicine, Research & Experimental

Atogepant Is Not Associated With Clinically Meaningful Alanine Aminotransferase Elevations in Healthy Adults

K. Chris Min et al.

Summary: This report evaluates the safety, tolerability, and pharmacokinetics of a once-daily supratherapeutic dose of atogepant in healthy participants. The study found that high oral doses of atogepant were safe and well-tolerated, with no clinically meaningful elevations in ALT levels observed during the treatment period.

CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2021)

Add to Collection

Article Clinical Neurology

The prevalence and impact of migraine and severe headache in the United States: Updated age, sex, and socioeconomic-specific estimates from government health surveys

Rebecca Burch et al.

Summary: Accurate estimates of the burden of migraine and severe headache are crucial for evidence-based decision-making about workforce needs and health resource distribution. The prevalence of migraine in the US has remained stable, with a higher impact in women of childbearing age and those of lower socioeconomic status. Many adults with migraine or severe headaches are disadvantaged, highlighting the need for improved funding for treatment provision and research to reduce the future burden of disease.

HEADACHE (2021)

Add to Collection

Article Medicine, General & Internal

Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial

Robert Croop et al.

Summary: Rimegepant was found to be effective for preventive treatment of migraine compared to placebo, with tolerability similar to that of placebo and no unexpected or serious safety issues noted.

LANCET (2021)

Add to Collection

Article Clinical Neurology

Risk of hypertension in erenumab-treated patients with migraine: Analyses of clinical trial and postmarketing data

David W. Dodick et al.

Summary: Clinical trials did not show an increased risk of hypertension with erenumab compared to placebo. Adverse event rates of hypertension reported with erenumab in the postmarketing setting were generally low. Additional data are needed to fully understand the risk of hypertension associated with erenumab.

HEADACHE (2021)

Add to Collection

Article Pharmacology & Pharmacy

Single-Dose Pharmacokinetics and Safety of Atogepant in Adults With Hepatic Impairment: Results From an Open-Label, Phase 1 Trial

Ramesh Boinpally et al.

Summary: This study investigated the pharmacokinetics and safety of Atogepant in participants with hepatic impairment, showing differences in absorption and elimination compared to those with normal hepatic function, but overall systemic exposure increase is not clinically relevant. The drug was found to be safe and did not lead to any clinically relevant changes in pharmacokinetics in participants with hepatic impairment.

CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2021)

Add to Collection

Article Anesthesiology

Efficacy and Tolerability of Calcitonin Gene-Related Peptide-Targeted Monoclonal Antibody Medications as Add-on Therapy to OnabotulinumtoxinA in Patients with Chronic Migraine

Fred Cohen et al.

Summary: The study demonstrated that adding CGRP-targeted mAb to onabot treatment in patients with chronic migraine resulted in further reductions in headache days, with good overall tolerability.

PAIN MEDICINE (2021)

Add to Collection

Article Clinical Neurology

Safety and efficacy of ubrogepant in participants with major cardiovascular risk factors in two single-attack phase 3 randomized trials: ACHIEVE I and II

Susan Hutchinson et al.

Summary: The study aimed to examine the safety and efficacy of ubrogepant for acute treatment of migraine across different cardiovascular disease risk categories. The results showed that the treatment effects of ubrogepant were consistent across various cardiovascular risk categories.

CEPHALALGIA (2021)

Add to Collection

Article Pharmacology & Pharmacy

Evaluation of the Pharmacokinetic Interaction and Safety of Atogepant Co-Administered with Acetaminophen or Naproxen in Healthy Participants: A Randomized Trial

Ramesh Boinpally et al.

Summary: This study confirmed that co-administration of atogepant with acetaminophen or naproxen was safe and well tolerated in healthy participants, with no observed drug-drug interactions.

CLINICAL DRUG INVESTIGATION (2021)

Add to Collection

Article Clinical Neurology

Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug-drug interaction study

Abhijeet Jakate et al.

Summary: The study evaluated the impact of two CGRP-targeted mAbs, erenumab and galcanezumab, on the PK profile, safety, and tolerability of ubrogepant in adults with migraine. The results showed that coadministration of ubrogepant with erenumab or galcanezumab did not significantly alter the PK profile of ubrogepant and had no safety concerns.

HEADACHE (2021)

Add to Collection

Article Pharmacology & Pharmacy

A Single Supratherapeutic Dose of Atogepant Does Not Affect Cardiac Repolarization in Healthy Adults: Results From a Randomized, Single-Dose, Phase 1 Crossover Trial

Ramesh Boinpally et al.

Summary: Atogepant, a selective oral CGRP receptor antagonist, was evaluated in a phase 1 crossover study for its cardiac repolarization effect. The study confirmed the safety and lack of impact on cardiac repolarization of a single supratherapeutic dose of Atogepant in healthy adults.

CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2021)

Add to Collection

Article Clinical Neurology

The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice

Jessica Ailani et al.

Summary: This update aims to incorporate recent research findings, expert consensus, and patient perspectives into updated guidance on the use of new acute and preventive treatments for migraine in adults. It provides practical recommendations based on expanded evidence base and emerging expert consensus, in the absence of a formal guideline.

HEADACHE (2021)

Add to Collection

Article Medicine, General & Internal

Atogepant for the Preventive Treatment of Migraine

Jessica Ailani et al.

Summary: Oral atogepant once daily was effective in reducing the number of migraine days and headache days over a period of 12 weeks, but may cause adverse events such as constipation and nausea. Longer and larger trials are needed to determine the effect and safety of atogepant for migraine prevention.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Clinical Neurology

Ubrogepant for the Acute Treatment of Migraine: Pooled Efficacy, Safety, and Tolerability From the ACHIEVE I and ACHIEVE II Phase 3 Randomized Trials

Susan Hutchinson et al.

Summary: The post hoc analysis of pooled data from the ACHIEVE trials demonstrates that ubrogepant 50 mg shows significant efficacy and safety in the acute treatment of migraine, providing pain relief and reducing migraine-associated symptoms effectively.

NEUROLOGY AND THERAPY (2021)

Add to Collection

Article Clinical Neurology

Characterisation of the calcitonin gene-related peptide receptor antagonists ubrogepant and atogepant in human isolated coronary, cerebral and middle meningeal arteries

Eloisa Rubio-Beltran et al.

CEPHALALGIA (2020)

Add to Collection

Review Pharmacology & Pharmacy

Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targeting

Anne-Sophie Wattiez et al.

EXPERT OPINION ON THERAPEUTIC TARGETS (2020)

Add to Collection

Article Clinical Neurology

Ubrogepant, an Acute Treatment for Migraine, Improved Patient-Reported Functional Disability and Satisfaction in 2 Single-Attack Phase 3 Randomized Trials, ACHIEVE I and II

David W. Dodick et al.

HEADACHE (2020)

Add to Collection

Editorial Material Clinical Neurology

Gepants

Deborah Tepper

HEADACHE (2020)

Add to Collection

Article Pharmacology & Pharmacy

Atogepant Has No Clinically Relevant Effects on the Pharmacokinetics of an Ethinyl Estradiol/Levonorgestrel Oral Contraceptive in Healthy Female Participants

Wendy Ankrom et al.

JOURNAL OF CLINICAL PHARMACOLOGY (2020)

Add to Collection

Article Clinical Neurology

Anti-migraine Calcitonin Gene-Related Peptide Receptor Antagonists Worsen Cerebral Ischemic Outcome in Mice

Inge A. Mulder et al.

ANNALS OF NEUROLOGY (2020)

Add to Collection

Article Clinical Neurology

Evaluation of the Pharmacokinetic Interaction of Ubrogepant Coadministered With Sumatriptan and of the Safety of Ubrogepant With Triptans

Abhijeet Jakate et al.

HEADACHE (2020)

Add to Collection

Article Clinical Neurology

The potential danger of blocking CGRP for treating migraine in CADASIL patients

Irene de Boer et al.

CEPHALALGIA (2020)

Add to Collection

Article Clinical Neurology

Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache

Edita Navratilova et al.

CEPHALALGIA (2020)

Add to Collection

Article Clinical Neurology

Differential medication overuse risk of novel anti-migraine therapeutics

Chonlawan Saengjaroentham et al.

BRAIN (2020)

Add to Collection

Article Clinical Neurology

Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine

Gary Berman et al.

HEADACHE (2020)

Add to Collection

Article Clinical Neurology

Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial

Peter J. Goadsby et al.

LANCET NEUROLOGY (2020)

Add to Collection

Review Clinical Neurology

Recent Advances in the Management of Cluster Headache

Maria Dolores Villar-Martinez et al.

CURRENT TREATMENT OPTIONS IN NEUROLOGY (2020)

Add to Collection

Editorial Material Clinical Neurology

Migraine remains second among the world's causes of disability, and first among young women: findings from GBD2019

T. J. Steiner et al.

JOURNAL OF HEADACHE AND PAIN (2020)

Add to Collection

Review Health Care Sciences & Services

Estimating the Economic Burden of Migraine on US Employers

Aylin Yucel et al.

AMERICAN JOURNAL OF MANAGED CARE (2020)

Add to Collection

Article Biochemistry & Molecular Biology

CGRP Induces Differential Regulation of Cytokines from Satellite Glial Cells in Trigeminal Ganglia and Orofacial Nociception

Shaista Afroz et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)

Add to Collection

Review Clinical Neurology

CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP?

Valentina Favoni et al.

JOURNAL OF HEADACHE AND PAIN (2019)

Add to Collection

Article Clinical Neurology

Pediatric vs. Adult Prodrome and Postdrome: A Window on Migraine Pathophysiology?

Jean-Christophe Cuvellier

FRONTIERS IN NEUROLOGY (2019)

Add to Collection

Review Clinical Neurology

Clinical features of visual migraine aura: a systematic review

Michele Viana et al.

JOURNAL OF HEADACHE AND PAIN (2019)

Add to Collection

Review Clinical Neurology

Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review

Hsiangkuo Yuan et al.

HEADACHE (2019)

Add to Collection

Article Medicine, General & Internal

Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial

Robert Croop et al.

LANCET (2019)

Add to Collection

Article Medicine, General & Internal

Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine

Richard B. Lipton et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Clinical Neurology

European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention

Simona Sacco et al.

JOURNAL OF HEADACHE AND PAIN (2019)

Add to Collection

Review Clinical Neurology

The big CGRP flood - sources, sinks and signalling sites in the trigeminovascular system

Karl Messlinger

JOURNAL OF HEADACHE AND PAIN (2018)

Add to Collection

Review Physiology

The Role of Calcitonin Gene Related Peptide (CGRP) in Neurogenic Vasodilation and Its Cardioprotective Effects

Zizheng Kee et al.

FRONTIERS IN PHYSIOLOGY (2018)

Add to Collection

Review Clinical Neurology

Triggers, Protectors, and Predictors in Episodic Migraine

Michael J. Marmura

CURRENT PAIN AND HEADACHE REPORTS (2018)

Add to Collection

Article Clinical Neurology

Migraine in America Symptoms and Treatment (MAST) Study: Baseline Study Methods, Treatment Patterns, and Gender Differences

Richard B. Lipton et al.

HEADACHE (2018)

Add to Collection

Editorial Material Clinical Neurology

Recommendations on the Use of Anti-CGRP Monoclonal Antibodies in Children and Adolescents

Christina L. Szperka et al.

HEADACHE (2018)

Add to Collection

Article Clinical Neurology

Overview of Neuropeptides: Awakening the Senses?

Andrew F. Russo

HEADACHE (2017)

Add to Collection

Review Anesthesiology

The role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine

Smriti Iyengar et al.

PAIN (2017)

Add to Collection

Article Pharmacology & Pharmacy

Binding and functional pharmacological characteristics of gepant-type antagonists in rat brain and mesenteric arteries

Majid Sheykhzade et al.

VASCULAR PHARMACOLOGY (2017)

Add to Collection

Review Oncology

CGRP Monoclonal Antibodies for Migraine: Rationale and Progress

Hsiangkuo Yuan et al.

BIODRUGS (2017)

Add to Collection

Article Biochemistry & Molecular Biology

Neuropeptide-Induced Mast Cell Degranulation and Characterization of Signaling Modulation in Response to IgE Conditioning

Benjamin M. Manning et al.

ACS CHEMICAL BIOLOGY (2016)

Add to Collection

Review Pharmacology & Pharmacy

Calcitonin Gene-Related Peptide (CGRP): A New Target for Migraine

Andrew F. Russo

ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 55 (2015)

Add to Collection

Article Neurosciences

Migraine: Multiple Processes, Complex Pathophysiology

Rami Burstein et al.

JOURNAL OF NEUROSCIENCE (2015)

Add to Collection

Article Anesthesiology

OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine

Eva Cernuda-Morollon et al.

PAIN (2015)

Add to Collection

Article Peripheral Vascular Disease

An Ongoing Role of α-Calcitonin Gene-Related Peptide as Part of a Protective Network Against Hypertension, Vascular Hypertrophy, and Oxidative Stress

Sarah-Jane Smillie et al.

HYPERTENSION (2014)

Add to Collection

Article Clinical Neurology

Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention

Tony W. Ho et al.

NEUROLOGY (2014)

Add to Collection

Review Physiology

CALCITONIN GENE-RELATED PEPTIDE: PHYSIOLOGY AND PATHOPHYSIOLOGY

F. A. Russell et al.

PHYSIOLOGICAL REVIEWS (2014)

Add to Collection

Article Biochemistry & Molecular Biology

The activation of the CGRP receptor

James Barwell et al.

BIOCHEMICAL SOCIETY TRANSACTIONS (2013)

Add to Collection

Review Biochemistry & Molecular Biology

Calcitonin gene-related peptide in migraine: intersection of peripheral inflammation and central modulation

Ann C. Raddant et al.

EXPERT REVIEWS IN MOLECULAR MEDICINE (2011)

Add to Collection

Article Clinical Neurology

Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura

Jakob Moller Hansen et al.

CEPHALALGIA (2010)

Add to Collection

Article Immunology

Pretreatment With Calcitonin Gene-Related Peptide Attenuates Hepatic Ischemia/Reperfusion Injury in Rats

S. W. Song et al.

TRANSPLANTATION PROCEEDINGS (2009)

Add to Collection

Article Pharmacology & Pharmacy

Topiramate inhibits trigeminovascular activation: an intravital microscopy study

S Akerman et al.

BRITISH JOURNAL OF PHARMACOLOGY (2005)

Add to Collection

Article Clinical Neurology

Sumatriptan causes parallel decrease in plasma calcitonin gene-related peptide (CGRP) concentration and migraine headache during nitroglycerin induced migraine attack

G Juhasz et al.

CEPHALALGIA (2005)

Add to Collection

Article Cardiac & Cardiovascular Systems

Calcitonin gene-related peptide in vivo positive inotropy is attributable to regional sympatho-stimulation and is blunted in congestive heart failure

T Katori et al.

CIRCULATION RESEARCH (2005)

Add to Collection

Article Peripheral Vascular Disease

Development of angiotensin II-induced hypertension: role of CGRP and its receptor

JP Li et al.

JOURNAL OF HYPERTENSION (2005)

Add to Collection

Article Peripheral Vascular Disease

Activation of the renin-angiotensin system in α-calcitonin gene-related peptide/calcitonin gene knockout mice

JP Li et al.

JOURNAL OF HYPERTENSION (2004)

Add to Collection

Article Clinical Neurology

CGRP may play a causative role in migraine

LH Lassen et al.

CEPHALALGIA (2002)

Add to Collection

Article Clinical Neurology

Nitric oxide metabolites, prostaglandins and trigeminal vasoactive peptides in internal jugular vein blood during spontaneous migraine attacks

P Sarchielli et al.

CEPHALALGIA (2000)

Add to Collection

© Peeref 2019-2024. All rights reserved.